Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-21-320239
Filing Date
2021-11-04
Accepted
2021-11-04 16:43:19
Documents
16
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A d230444d10ka.htm   iXBRL 10-K/A 61510
2 EX-31.1 d230444dex311.htm EX-31.1 11349
3 EX-31.2 d230444dex312.htm EX-31.2 11338
  Complete submission text file 0001193125-21-320239.txt   270099

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ngm-20201231.xsd EX-101.SCH 4650
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ngm-20201231_cal.xml EX-101.CAL 659
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ngm-20201231_def.xml EX-101.DEF 1664
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE ngm-20201231_lab.xml EX-101.LAB 20890
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ngm-20201231_pre.xml EX-101.PRE 16563
9 EXTRACTED XBRL INSTANCE DOCUMENT d230444d10ka_htm.xml XML 7170
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38853 | Film No.: 211380571
SIC: 2834 Pharmaceutical Preparations